Clinical Cohort Analysis of Germline EGFR T790M Demonstrates Penetrance Across Ethnicities and Races, Sexes, and Ages
- 1 November 2020
- journal article
- research article
- Published by American Society of Clinical Oncology (ASCO) in JCO Precision Oncology
- Vol. 4 (4) , 170-175
Abstract
No abstract availableThis publication has 20 references indexed in Scilit:
- Osimertinib in Untreated EGFR -Mutated Advanced Non–Small-Cell Lung CancerNew England Journal of Medicine, 2018
- Discrimination of Germline EGFR T790M Mutations in Plasma Cell-Free DNA Allows Study of Prevalence Across 31,414 Cancer PatientsClinical Cancer Research, 2017
- Germline Mutations in DNA Repair Genes in Lung AdenocarcinomaJournal of Thoracic Oncology, 2017
- Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2016
- Germline Mutation of T790M and Dual/Multiple EGFR Mutations in Patients With Lung AdenocarcinomaClinical Lung Cancer, 2016
- Hereditary Lung Cancer Syndrome Targets Never Smokers with Germline EGFR Gene T790M MutationsJournal of Thoracic Oncology, 2014
- Germline EGFR T790M Mutation Found in Multiple Members of a Familial CohortJournal of Thoracic Oncology, 2014
- Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFRNature Genetics, 2005
- Acquired Resistance of Lung Adenocarcinomas to Gefitinib or Erlotinib Is Associated with a Second Mutation in the EGFR Kinase DomainPLOS Medicine, 2005
- Combined Targeting of the Estrogen Receptor and the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer Shows Enhanced Antiproliferative EffectsCancer Research, 2005